[email protected]
CDI - Contrive Datum Insights
Agriculture

Rodenticides Market Size, Growth Rate and Forecast to 2034: Drivers, Restraints and Segment Shares

The rodenticides market grows at 4.53% to USD 9.08 billion by 2034, with second-generation anticoagulants holding 52% of 2025 revenue and fertility control and biological compounds growing fastest.

Published: Industry: AgricultureRead time: ~5 min

The rodenticides market reaches USD 9.08 billion by 2034, growing at a CAGR of 4.53% from a 2025 base. That rate is a blend. The lines inside it move at very different speeds, and the supply of anticoagulant products carries most of the revenue. This analysis sets out the size, the rate, the forces behind it and the case for a slower outcome. Full segment detail sits in the rodenticides market report.

Market size and growth rate

The market stood at USD 4.85 billion in 2020 and USD 5.88 billion in 2024. In 2025, the base year, it reached USD 6.1 billion. The 2020 to 2025 record shows 4.69% compound growth before the forecast period begins.

From that 2025 base, the forecast carries 4.53% a year through 2034, ending at USD 9.08 billion. The forecast period runs 2026 to 2034.

The rate is held flat across the forecast and is not ramped upward. The reason is in the history: growth is already visible in the record, so the projection does not have to assume an acceleration. The uncertainty in the number sits in the product mix, not in whether the market grows at all.

Two alternative outcomes bracket the base case. The bull case reaches USD 10.22 billion by 2034. The bear case lands at USD 7.95 billion. Both start from the same USD 6.1 billion in 2025.

What is driving it

The headline 4.53% is a weighted result. No single product line achieves it. The fastest line on the active ingredient type axis is Fertility Control and Biological compounds, growing at 12.53%. At the other end, First-Generation Anticoagulants grows at 0.5%.

Fertility Control and Biological compounds rises from USD 0.183 billion in 2025 to USD 0.545 billion in 2034. Its share of revenue moves from 3% to 6%. The line is small today, and the growth rate is what gives it weight in the forecast.

A supplier's exposure to that axis decides whether it grows with the market or below it. A portfolio concentrated in older chemistries tracks under 4.53%. A portfolio tilted toward biological and fertility control products tracks above it.

The same pattern appears in neighbouring crop and pest inputs. In the nematicides market, Microbial Biological Nematicides grows at 11.08% against 6.31% for the market. The direction of travel in pest control chemistry is toward biological products in both.

The pattern is also not limited to chemicals. In the agriculture drone market, Drone-as-a-Service grows at 20.35% against 15.7% for the whole market. In each of these markets the blended rate depends on one faster line, and the rodenticides market follows the same logic at a lower speed.

What could slow it

The restraint case rests on three conditions occurring together. Major markets impose sharp outdoor and consumer anticoagulant bans. Resistance spreads faster than new active ingredients are approved. Trapping and exclusion methods take volume from bait.

On those assumptions, 2034 revenue lands at USD 7.95 billion against the USD 9.08 billion base case. The starting point is the same USD 6.1 billion in 2025. The market still grows in this case; it simply grows more slowly.

The structure of the base explains why the restraint matters. Second-Generation Anticoagulants carries 52% of 2025 revenue at USD 3.172 billion. It compounds at 3.83% against 4.53% for the market. Its share falls to 48.99% by 2034, even as its revenue rises to USD 4.448 billion.

Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it. Anything that changes demand for this one line changes the headline number. Nothing else on the axis carries the same weight.

That is the practical meaning of a regulatory ban on outdoor and consumer anticoagulant use. The exposure is concentrated, not spread across the axis.

The upside has a mirror image. If anticoagulant registrations stay in place under professional-use conditions, urban infestation pressure keeps rising and non-anticoagulant products gain approvals faster than expected, the market reaches USD 10.22 billion by 2034.

Where the growth sits

The active ingredient type axis shows the split of 2025 revenue:

  • Second-Generation Anticoagulants: 52%
  • First-Generation Anticoagulants: 17%
  • Fumigants and Other Chemicals: 16%
  • Non-Anticoagulants: 12%
  • Fertility Control and Biological: 3%

The opening for new positions is on this axis and not the regional one. Share moves toward Fertility Control and Biological, from 3% in 2025 to 6% in 2034. Taking a position there does not require displacing whoever holds Second-Generation Anticoagulants, the harder and more expensive fight.

The report also segments the market by form, application, target species, end user, distribution channel, dispensing method, pack size and regulatory use class. Applications run from agriculture and crop protection to livestock and poultry farms, commercial buildings and conservation and island eradication. Target species include the Norway rat, roof rat and house mouse.

Regionally, the supplied data points to a concentrated picture in North America. The region is worth USD 1.525 billion in 2025, and USD 1.22 billion of that is the United States. The United States holds 80% of the region. Read as a region, North America looks diversified. Read by weight, it is not, and the regional forecast inherits whatever happens in that one market.

Europe, Asia Pacific, Latin America and the Middle East and Africa are all covered in the report. For buyers comparing agricultural technology categories, the smart greenhouse market shows a similar structure: Software grows at 15.07% against 10.51% for the market, and Europe leads regional revenue at 33%.

Taken together, the rodenticides market is a steady grower with a concentrated base. Most of the revenue sits in one product line, most of the upside sits in a small one, and the gap between the base case and the bear case depends on regulation of the larger line.